Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan 80/5 vs 40/5 FDC in Japanese Hypertension
NCT01286558Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2011
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telmisartan in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough at 8 weeks. Started Jan 2011; status: completed.
02
Drugs
telmisartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT01286558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01286558.